CN112493491A - 牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用 - Google Patents
牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用 Download PDFInfo
- Publication number
- CN112493491A CN112493491A CN202011328371.4A CN202011328371A CN112493491A CN 112493491 A CN112493491 A CN 112493491A CN 202011328371 A CN202011328371 A CN 202011328371A CN 112493491 A CN112493491 A CN 112493491A
- Authority
- CN
- China
- Prior art keywords
- magnesium
- supplement
- taurine
- bone health
- taurate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 title claims abstract description 32
- 239000013589 supplement Substances 0.000 title claims abstract description 17
- 230000037180 bone health Effects 0.000 title claims abstract description 16
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 15
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229960003080 taurine Drugs 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 5
- 239000000347 magnesium hydroxide Substances 0.000 claims description 5
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract description 28
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract description 14
- 235000019341 magnesium sulphate Nutrition 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 210000000689 upper leg Anatomy 0.000 description 8
- 239000011575 calcium Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SDHMGKANHNMOSS-UHFFFAOYSA-N 1-aminoethanesulfonic acid Chemical compound CC(N)S(O)(=O)=O SDHMGKANHNMOSS-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用。经过动物实验证明，牛磺酸镁有助于改善骨骼健康和预防骨质疏松症，并且效果比单独的硫酸镁或牛磺酸效果要好。将牛磺酸镁应用于营养补充剂中，可以改善使用者的改善骨骼健康，并且预防骨质疏松症。
Description
技术领域
本发明涉及牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用，属于食品技术领域。
背景技术
镁是人体内含量最多的阳离子之一，是人体细胞内占第二位(仅次于钾)的阳离子，镁参与蛋白质的合成，镁能激活体内多种酶，能调节神经肌肉和中枢神经系统的活动，保障心机正常收缩，镁几乎参与人体内所有的新陈代谢。人体缺镁可引起许多疾病，反之，镁可治疗上述相关的疾病。作为补充镁离子的首选药—硫酸镁在临床上应用作为广泛。
牛磺酸是人体所必需的十八种氨基酸之一，是一种化学结构简单的含硫氨基酸,为α-氨基乙磺酸,不参与蛋白质组成和代谢,而是以游离形式存在或与胆汁酸形成复合物。牛磺酸在生物体内参与一系列的生理学过程,如与胆汁酸结合、调节渗透压、外源化合物的解毒、细胞膜的稳定、细胞钙流动调节、神经发育、神经兴奋性调节、神经保护、抗氧化和抗心律失常等，具有广泛的生物活性，对血管、神经、肌肉运动、内分泌、免疫等系统发挥良好的调节作用，特别对婴儿大脑和视觉发育有重要的作用。
发明内容
为了克服现有技术的不足，本发明提供了牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用。
本发明是通过以下技术方案来实现的：
牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用。
所述牛磺酸镁是通过以下步骤获得的：
(1)将氢氧化镁与水混合后制成混悬液，加热至75-85℃，备用；
(2)将牛磺酸与水混合制成牛磺酸水溶液，保持温度在75-85℃，缓慢加入步骤(1)中75-85℃的混悬液，添加完成后继续加热，回流反应5-10min后过滤，得到滤液；
(3)将滤液浓缩后，向滤液中加入甲醇，搅拌后在0-4℃中静置24h，再次过滤，将过滤后的澄清液浓缩，得到最后的牛磺酸镁。
所述牛磺酸镁是通过以下步骤获得的：
(1)将氢氧化镁1.6g与水30-50ml混合后制成混悬液，加热至75-85℃，备用；
(2)将牛磺酸5g与水100-125ml混合制成牛磺酸水溶液，保持温度在75-85℃，缓慢加入步骤(1)中75-85℃的混悬液，添加完成后继续加热，回流反应5-10min后过滤，得到滤液；
(3)将滤液浓缩后，向滤液中加入甲醇15-20ml，搅拌后在0-4℃中静置24h，再次过滤，将过滤后的澄清液浓缩，得到最后的牛磺酸镁。
所述的牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用，所述牛磺酸镁在补充剂中的添加量为10-30％。
经过动物实验证明，牛磺酸镁有助于改善骨骼健康和预防骨质疏松症，并且效果比单独的硫酸镁或牛磺酸效果要好。将牛磺酸镁应用于营养补充剂中，可以改善使用者的改善骨骼健康，并且预防骨质疏松症。
具体实施方式
下面对本发明作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案，而不能以此来限制本发明的保护范围。
牛磺酸镁制备方法如下：
(1)将氢氧化镁1.6g与水30-50ml混合后制成混悬液，加热至75-85℃，备用；
(2)将牛磺酸5g与水100-125ml混合制成牛磺酸水溶液，保持温度在75-85℃，缓慢加入步骤(1)中75-85℃的混悬液，添加完成后继续加热，回流反应5-10min后过滤，得到滤液；
(3)将滤液浓缩后，向滤液中加入甲醇15-20ml，搅拌后在0-4℃中静置24h，再次过滤，将过滤后的澄清液浓缩，得到最后的牛磺酸镁。
补充剂的制备方法如下：
将牛磺酸镁与补充剂其它成分混合后得到补充剂，其中牛磺酸镁的添加量占补充剂总重量的10-30％。
牛磺酸镁对骨骼健康的影响
1、材料和方法
1.1实验动物
SD种雄雌性健康大鼠，体重60-75g。
1.2试验方法
造模方法：大鼠行双侧卵巢切除术去势，同时给予特殊饲料，造成低密度底下模型。特殊饲料配方为：酪蛋白23％、DL-蛋氨酸0.3％、玉米淀粉32％、蔗糖30％、玉米油10％、混合矿物盐3.5％和混合维生素1.2％。
动物适应性饲养3d后开始实验分组观察。将大鼠随机分为模型对照组、牛磺酸组、硫酸镁组、硫酸镁+牛磺酸组、牛磺酸镁低、中、高剂量组、阳性组，每组10只，给药剂量见表1。模型组灌胃给予溶剂0.5％羧甲基纤维素钠溶液作为对照。硫酸镁+牛磺酸组中硫酸镁和牛磺酸的重量比为1:1。阳性组给予的是碳酸钙。
大鼠每日自由摄食给样，每鼠保证有充足饲料和饮水，饮用去离子水以免从饮水中获得钙，连续3个月。
实验末摘取眼球取血，2000r/min离心，吸取上清得到血清，分别取出左侧股骨和右侧股骨，于105℃烘箱中，烤至恒重，称骨测量。采用骨密度仪测定股骨中点和股骨远心端密度。采用原子吸收分光光度法测定右股骨钙含量。取血清0.5ml，用全自动生化分析仪检测血清碱性磷酸酶(ALP)、钙(Ca)和磷(P)。
表1
1.3统计学处理
实验结果均以x±s表示，采用单因素方差分析进行组间显著性比较，样本均数间比较采用t检验。*表示P＜0.05，表明给药组与模型组比较有显著性差异；**表示P＜0.01，表明给药组与模型组比较有极显著性差异。
2、结果
表2牛磺酸镁对骨密度的影响
由表2可见，与模型组比较，各给药组的骨钙含量均有升高，股骨远端有骨密度和股骨中点密度均有提高。能够看到同时给药硫酸镁和牛磺酸比单独给药硫酸镁或牛磺酸效果差不多，但是在同等剂量下，牛磺酸镁的效果优于硫酸镁和牛磺酸的效果，也优于硫酸镁+牛磺酸组。
表3
由表3可见，与模型组比较，各给药组大鼠的血清钙浓度和磷浓度均有升高，而碱性磷酸酶活性均有下降。能够看到同时给药硫酸镁和牛磺酸比单独给药硫酸镁或牛磺酸效果差不多，但是在同等剂量下，牛磺酸镁的效果优于硫酸镁和牛磺酸的效果，也优于硫酸镁+牛磺酸组。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明技术原理的前提下，还可以做出若干改进和变形，这些改进和变形也应视为本发明的保护范围。
Claims (4)
1.牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用。
2.根据权利要求1所述的牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用，其特征是，所述牛磺酸镁是通过以下步骤获得的：
(1)将氢氧化镁与水混合后制成混悬液，加热至75-85℃，备用；
(2)将牛磺酸与水混合制成牛磺酸水溶液，保持温度在75-85℃，缓慢加入步骤(1)中75-85℃的混悬液，添加完成后继续加热，回流反应5-10min后过滤，得到滤液；
(3)将滤液浓缩后，向滤液中加入甲醇，搅拌后在0-4℃中静置24h，再次过滤，将过滤后的澄清液浓缩，得到最后的牛磺酸镁。
3.根据权利要求2所述的牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用，其特征是，所述牛磺酸镁是通过以下步骤获得的：
(1)将氢氧化镁1.6g与水30-50ml混合后制成混悬液，加热至75-85℃，备用；
(2)将牛磺酸5g与水100-125ml混合制成牛磺酸水溶液，保持温度在75-85℃，缓慢加入步骤(1)中75-85℃的混悬液，添加完成后继续加热，回流反应5-10min后过滤，得到滤液；
(3)将滤液浓缩后，向滤液中加入甲醇15-20ml，搅拌后在0-4℃中静置24h，再次过滤，将过滤后的澄清液浓缩，得到最后的牛磺酸镁。
4.根据权利要求3所述的牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用，其特征是，所述牛磺酸镁在补充剂中的添加量为10-30％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011328371.4A CN112493491A (zh) | 2020-11-24 | 2020-11-24 | 牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011328371.4A CN112493491A (zh) | 2020-11-24 | 2020-11-24 | 牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112493491A true CN112493491A (zh) | 2021-03-16 |
Family
ID=74958245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011328371.4A Pending CN112493491A (zh) | 2020-11-24 | 2020-11-24 | 牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112493491A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5582839A (en) * | 1995-04-18 | 1996-12-10 | Nutrition 21 | Magnesium taurate and other mineral taurates |
| CN101428056A (zh) * | 2008-12-16 | 2009-05-13 | 江西本草天工科技有限责任公司 | 一种改善中老年女性骨质疏松症的保健制剂及制备方法 |
| US20160192689A1 (en) * | 2013-07-31 | 2016-07-07 | Wikifoods, Inc. | Encapsulated functional food compositions |
-
2020
- 2020-11-24 CN CN202011328371.4A patent/CN112493491A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5582839A (en) * | 1995-04-18 | 1996-12-10 | Nutrition 21 | Magnesium taurate and other mineral taurates |
| CN101428056A (zh) * | 2008-12-16 | 2009-05-13 | 江西本草天工科技有限责任公司 | 一种改善中老年女性骨质疏松症的保健制剂及制备方法 |
| US20160192689A1 (en) * | 2013-07-31 | 2016-07-07 | Wikifoods, Inc. | Encapsulated functional food compositions |
Non-Patent Citations (1)
| Title |
|---|
| 苗宇等: "牛磺酸镁盐制备工艺的改进", 《中国现代应用药学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106035983B (zh) | 一种饲料添加剂纳米小肽螯合铜的制备方法 | |
| CA2743406A1 (en) | Fracture repair promoter | |
| EP1172373B1 (en) | Method for preparing zinc-oligopeptide easily absorbable by the human body | |
| CN101842385B (zh) | 破骨细胞形成抑制用食品原材料 | |
| CN101279089A (zh) | 阿胶钙组合物及其制备方法 | |
| US4208405A (en) | Trace element composition for iron deficiency anemia | |
| US5677461A (en) | Method for producing chromium picolinate complex | |
| CN112493491A (zh) | 牛磺酸镁在制备改善骨骼健康和预防骨质疏松症的补充剂中的应用 | |
| CN114431304A (zh) | 一种以驴乳为基料的二段婴儿配方乳粉及其制备方法 | |
| CN1711856A (zh) | 铁红血酸奶片 | |
| EP0492183B1 (de) | Phenylalaninfreie Säuglings- und Kleinkindnahrungsgrundlage | |
| CN110179127B (zh) | 一种促铁锌钙吸收的营养强化剂及制备方法 | |
| TWI690505B (zh) | 胺基酸快速螯合鈣之方法 | |
| CN112535294A (zh) | 牛磺酸镁在制备改善心血管健康的营养补充剂中的应用 | |
| CN102342400A (zh) | 高钙木糖醇 | |
| CN105614078A (zh) | 一种调节动物机体电解质平衡与酸碱平衡的组合物及其应用 | |
| CN101868475A (zh) | 骨吸收抑制用食品原材料 | |
| CN1775733A (zh) | 神经酸钙及其制备方法与应用 | |
| MERRILL | Nutrition in chronic renal failure | |
| CN1403093A (zh) | 以双金属氧化物为载体的口服补钒剂及其制备与使用方法 | |
| CN1189338A (zh) | 络合钙及其制造方法 | |
| CN1068506C (zh) | 一种多元素多肽营养品及制备方法 | |
| CN114403298A (zh) | 一种宠物用黄芪多糖营养口服液及其制备方法 | |
| CN101229218A (zh) | 用于治疗糖尿病的钒复方组合物及其制造方法 | |
| CN115893459A (zh) | 一种多功能水溶性纳米氢氧化镁原液的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210316 |